A lack of the protein beta-arrestin 1 reduces the ability of pulmonary arteries to widen, leading to pulmonary hypertension (PH), according to a new study in mice. The study found that when beta-arrestin 1 is missing, the signaling pathway that drives the widening of pulmonary arteries, the blood vessels…
News
A clinical trial testing mosliciguat, an inhaled therapy for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD), has wrapped up enrollment, and in less than one year since treating the first participant. That announcement was made by Pulmovant, the company developing the drug…
Cereno Scientific announced it will broaden development of its experimental treatment CS014 to include pulmonary hypertension associated with interstitial lung disease (PH-ILD). Cereno had previously focused development of CS014 on idiopathic pulmonary fibrosis (IPF), a condition marked by progressive scarring (fibrosis) of the lungs with no known…
Artificial intelligence (AI) tools developed by Etiometry may help to predict, among other outcomes, the length of a patient’s hospital stay following surgery among people with chronic thromboembolic pulmonary hypertension (CTEPH). As such, these tools could potentially be used to improve patient care, and better monitor post-surgery recovery,…
A life-support machine that temporarily replaces the heart and lungs — known as extracorporeal membrane oxygenation (ECMO) — boosts survival among pregnant women who develop severe pulmonary arterial hypertension (PAH). That’s according to a case series and literature review that found ECMO use in pregnancy-related PAH has improved survival…
Echinacoside (ECH), a naturally occurring compound derived from certain plants, particularly echinacea, was shown to ease the signs and symptoms of pulmonary arterial hypertension (PAH) in rats in a laboratory study. The researchers found that ECH worked by normalizing calcium signaling in the muscle cells lining blood vessels, which…
An expert panel convened by the American Lung Association and the Pulmonary Hypertension Association has developed practical flowcharts to help U.S. healthcare providers diagnose and treat pulmonary hypertension (PH). The meeting aimed to guide providers through the most recent European guidelines for PH diagnosis and treatment. The…
A part of NOTCH3, a protein involved in disease-related alterations in blood vessels, may be a biomarker of idiopathic pulmonary arterial hypertension (iPAH), a rare type of pulmonary hypertension (PH) that’s hard to diagnose, a recent study suggests. The researchers found that blood levels of the extracellular, or outside-the-cell,…
In people with pulmonary arterial hypertension (PAH), adding Winrevair (sotatercept-csrk) to standard therapy was linked to longer survival, fewer safety events, and a lower need for lung transplant compared with standard therapy alone, according to new real-world data. “These findings extend clinical trial evidence, suggesting sotatercept [Winrevair] offers meaningful…
Levels of the enzyme PRDX2 increase as a protective response in chronic thromboembolic pulmonary hypertension (CTEPH) and help reduce damage to blood vessels in the lungs, a new study in laboratory rats has found. The researchers discovered that the antioxidant enzyme worked to reduce vessel damage by limiting inflammation,…
A weight-based dose regimen of Uptravi (selexipag) for children with pulmonary arterial hypertension (PAH) achieves drug exposure similar to that of the standard adult dose regimen, according to results from a Phase 2 clinical trial. The study also found that the weight-based Uptravi regimen for kids is comparable…
Yutrepia, an inhaled dry powder formulation of treprostinil that won regulatory approval in the U.S. in May 2025, was prescribed to more than 2,800 patients through December of last year, according to its developer Liquidia. Overall, more than 2,200 patients have started treatment, per the biopharmaceutical company, which…
